Basilea Pharmaceutica AG
SIX:BSLN
Basilea Pharmaceutica AG
Intangible Assets
Basilea Pharmaceutica AG
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Intangible Assets
CHf371k
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
2%
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Intangible Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Intangible Assets
CHf29.8m
|
CAGR 3-Years
26%
|
CAGR 5-Years
107%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Intangible Assets
CHf17.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Intangible Assets
CHf30.6m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
Glance View
Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.
See Also
What is Basilea Pharmaceutica AG's Intangible Assets?
Intangible Assets
371k
CHF
Based on the financial report for Dec 31, 2025, Basilea Pharmaceutica AG's Intangible Assets amounts to 371k CHF.
What is Basilea Pharmaceutica AG's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
2%
Over the last year, the Intangible Assets growth was -1%. The average annual Intangible Assets growth rates for Basilea Pharmaceutica AG have been -14% over the past three years , -11% over the past five years , and 2% over the past ten years .
